

Labetuzumab

Cat. No.:	HY-P99160
CAS No.:	219649-07-7
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy ^[1] .	
IC₅₀ & Target	CEA ^[1] .	
In Vivo	Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Female nu/nu mice (6 to 8-week-old; inject TT cells) ^[1] .
	Dosage:	0.5 mg/rat
	Administration:	Intravenous injection; single (1 day post-tumor cell injection)
	Result:	Significantly delayed growth of tumor, and led to 64%-70% inhibition of tumor size between days 32 and 60.

REFERENCES

[1]. Stein R, et al. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. *Mol Cancer Ther.* 2004 Dec;3(12):1559-64.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA